Dicerna™ to Present at the H.C. Wainwright Global Life Sciences Conference

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Dicerna™
Pharmaceuticals, Inc. (Nasdaq:DRNA) (the “Company” or “Dicerna”), a
leading developer of investigational ribonucleic acid interference
(RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D.,
president and chief executive officer, will present a corporate update
at the H.C. Wainwright Global Life Sciences Conference on Monday, April
8, 2019 at 1:40 pm GMT. The conference will be held April 7-9, 2019 in
London.

A live audio webcast of the presentation will be accessible within the
Investors & Media section on the Dicerna website at www.dicerna.com.
An archived replay of the webcast will be available on the Company’s
website after the conference.

About Dicerna™ Pharmaceuticals, Inc.

Dicerna™ Pharmaceuticals, Inc., is a biopharmaceutical company focused
on the discovery and development of innovative, subcutaneously delivered
RNAi-based therapeutics for the treatment of diseases involving the
liver, including rare diseases, chronic liver diseases, cardiovascular
diseases and viral infectious diseases. Dicerna is leveraging its
proprietary GalXC™ RNAi technology platform to build a broad pipeline in
these core therapeutic areas, focusing on target genes where connections
between these genes and diseases are well understood and documented.
Dicerna intends to discover, develop and commercialize novel
therapeutics either on its own or in collaboration with pharmaceutical
partners. Dicerna has strategic collaborations with Eli Lilly and
Company, Alexion Pharmaceuticals, Inc. and Boehringer Ingelheim
International GmbH. For more information, please visit www.dicerna.com.

Contacts

Rebecca Peterson
Head of Corporate Communications
Dicerna
Pharmaceuticals, Inc.
Ph: 617-612-6235
[email protected]